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Introduction: Many efforts have been made to detect local 
relapse (LR) in the follow-up after stereotactic body radiother-
apy (SBRT) for non–small-cell lung cancer (NSCLC) although 
limited data are available on its treatment and prognosis. We 
aimed to characterize treatment options and clarify long-term 
outcomes of isolated LR after SBRT for patients with clinical 
stage I NSCLC.
Methods: We reviewed our institutional database in search of 
patients with isolated LR after SBRT for clinical stage I NSCLC at 
our institution between 1999 and 2013. Patient characteristics were 
compared with Mann–Whitney U test, χ2 test, or Fisher’s exact test as 
appropriate. Survival outcomes were estimated with Kaplan–Meier 
method. Potential prognostic factors were investigated using Cox 
proportional hazard model.
Results: Of 308 patients undergoing SBRT for clinical stage I 
NSCLC, 49 patients were identiﬁed to have isolated LR. Twelve 
patients underwent salvage surgery, none underwent radiotherapy, 
and eight patients received chemotherapy, whereas 29 patients 
received best supportive care. No patient characteristic except 
operability was signiﬁcantly related with patient selection for 
LR treatments. Five-year overall survival (OS) rate of the whole 
cohort was 47.9% from SBRT and 25.7% from LR. Salvage sur-
gery was associated with improved OS after LR (p = 0.014), and 
5-year OS for patients undergoing salvage surgery was 79.5% 
from LR.
Conclusions: It was conﬁrmed that our patient selection for salvage 
surgery for isolated LR was associated with favorable survival out-
comes. Operability based on multidisciplinary conferences, rather 
than measurable patient characteristics, is essential for appropriate 
patient selection for salvage surgery.
Key Words: Non–small-cell lung cancer, Surgery, Radiotherapy, 
Chemotherapy.
(J Thorac Oncol. 2015;10: 1616–1624)
Although video-assisted thoracoscopic surgery (VATS) lobectomy offers favorable survival outcome in operable 
patients,1 stereotactic body radiotherapy (SBRT) or stereotac-
tic ablative radiotherapy has been increasingly recognized as a 
favorable alternative to surgical resection for early-stage non–
small-cell lung cancer (NSCLC) in patients who are not ideal 
operative candidates.2–4
The rate of local relapse (LR) after SBRT for stage I 
NSCLC is 4% to 11.9% at 3 years5–7 and 10.5% to 28.3% at 
5 years.8,9 Many efforts have been made to identify patients 
at higher risk of LR and, for example, previously reported 
risk factors of LR after SBRT included a larger tumor size10 
and a lower retention index of fluorodeoxyglucose-positron 
emission tomography (FDG-PET).11 Moreover, to allow early 
detection of LR and potentially cure LR, high-risk radiologic 
changes in the follow-up have been identiﬁed and discussed 
extensively.12–14
There is a dearth of data on management of isolated LR 
after SBRT. Unlike local recurrence after surgical resection 
of NSCLC, for which local treatments (surgery or radiother-
apy) are indicated,15,16 LR after SBRT for NSCLC presents a 
dilemma because local treatments for this patient cohort are 
challenging: most SBRT patients are inoperable and repeating 
SBRT or offering conventional radiotherapy in the same area 
is a safety concern and increases the risk of toxicity. One study 
showed that repeat SBRT for LR was safe17 and achieved rea-
sonable local control although long-term survival outcomes 
remain unknown. Likewise, salvage surgery for isolated LR 
can be undertaken at low risk in operable patients,18–21 whereas 
long-term outcomes have remained to be determined. To date, 
no survival outcomes were reported in patients treated with 
chemotherapy or best supportive care (BSC) for isolated LR.
Salvage treatments for LR present a challenge; however, 
a portion of this patient cohort might be effectively treated, 
and favorably long-term survival may be achieved. In this 
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study, we aim to characterize treatment options and clarify 
long-term survival outcome in patients with isolated LR after 
SBRT for clinical stage I NSCLC.
PATIENTS AND METHODS
Approval of this study was granted by Institutional 
Review Board of Kyoto University Hospital. The requirement 
for patient consent was waived. Retrospective chart review 
was performed on the prospectively maintained database 
in Department of Radiation Oncology and Image-Applied 
Therapy and Department of Thoracic Surgery at Kyoto 
University Hospital.
Included in this study were patients who are found to 
have isolated LR in the follow-up after undergoing SBRT 
for a previously untreated, solitary, and peripheral clinical 
stage I (T1N0M0 or T2aN0M0) NSCLC and negative lymph 
node staging with PET-computed tomography (CT) at Kyoto 
University Hospital between January 1999 and December 
2013. Selection of patients with clinical stage I NSCLC was 
based on American Joint Committee of Cancer 7th edition 
staging manual.
Patients found to have LR with simultaneous regional 
(mediastinal lymph node) or distant relapse and patients found 
to have LR after regional or distant relapse were excluded. 
Patients with the initial tumor diameter larger than 5 cm, mul-
tiple synchronous lung cancers, typical or atypical carcinoid 
tumors, and small-cell lung cancer were also excluded.
For SBRT, the patient was immobilized with a stereotac-
tic body frame (Elekta, Stockholm, Sweden). The internal tar-
get volume was determined considering CT with a slow scan 
technique or 4D CT technique and tumor motion assessed 
by radiograph fluoroscopy. The planning target volume was 
deﬁned as the internal target volume plus 5-mm margin. 
Irradiation was performed with 6-MV X-ray beams from a 
linear accelerator (Clinac 2300 C/D; Varian Medical Systems 
till April 2008: Novalis; BrainLab AG, Munich, Germany, 
thereafter) in multiple noncoplanar static ports.
Medical comorbidity was assessed by Charlson comor-
bidity index,22 which has been validated in patients undergoing 
either surgery23 or SBRT24 for lung cancer. Overall survival 
(OS) was calculated from the date of start of initial SBRT 
and from LR to death due to any cause or the last follow-up. 
Cancer-speciﬁc survival (CSS) was calculated from the date 
of start of initial SBRT and from LR to death from recurrence 
of the treated NSCLC or to the last follow-up. All patients 
were followed up with physical examination and chest CT 
and/or FDG-PET (if indicated), every 2 to 4 months in the 
ﬁrst posttreatment year, every 6 months in the second to the 
ﬁfth year, and annually thereafter. LR was deﬁned primarily 
as an enlargement of the local tumor on CT that continued for 
at least 6 months or as a maximal standardized uptake value 
(SUVmax) on FDG-PET greater than 5 at 6 months, occasion-
ally with histologic conﬁrmation. FDG-PET was obtained at 
the discretion of the radiologist.
Statistical Analysis
Continuous variables are reported as a median. Patients’ 
characteristics were compared using Mann–Whitney U test, 
χ2 test, or Fisher’s exact test as appropriate. The median fol-
low-up time was calculated using the reverse Kaplan–Meier 
method for potential follow-up. OS and CSS were estimated 
with Kaplan–Meier method. Potential prognostic factors of 
OS and CSS from LR were analyzed with Cox proportional 
hazard models. The p values less than 0.05 were considered 
statistically signiﬁcant. Variables with a signiﬁcant p value in 
univariate analysis were included in multivariate analysis. We 
used JMP Version 11.0.1(copyright 2008, SAS Institute Inc., 
Cary, NC) for statistical analysis.
RESULTS
Between 1999 and 2013, 308 patients underwent SBRT 
for clinical stage I NSCLC, and of these, 49 patients were 
found to have isolated LR during at least 1 year of follow-up. 
Seventeen patients (34%) of 49 patients in this study had his-
tologically veriﬁed LR. Twelve patients underwent salvage 
surgery, none underwent radiotherapy, and eight patients 
received chemotherapy, whereas 29 patients received BSC. 
For reference, the median OS from SBRT of the total SBRT-
treated cohort (N = 308) was 48.8 months, and 5-year OS 
from SBRT was 43.3%. Of 308 patients, 86 were found to 
have distant relapse. Pretreatment patient characteristics at 
LR are shown in Table 1. A signiﬁcant difference was found 
only in operability among treatment groups. Follow-up was 
complete in all 49 patients. The median follow-up periods 
for the whole patient cohort were 6.7 years from SBRT and 
4.3 years from LR.
Salvage Surgery for Isolated LR
Salvage surgery was performed in 12 patients. Patient 
demographics and perioperative outcomes undergoing sal-
vage surgery are summarized in Table 2. Nine patients were 
considered operable at the initial evaluation but rejected sur-
gery upfront. Three patients were initially (at SBRT) consid-
ered inoperable for the following reasons. One patient was 
considered inoperable from a surgical standpoint (a history 
of an ipsilateral thoracotomy), another from an oncological 
standpoint (a previous stage IV NSCLC under chemother-
apy), and the other from a medical standpoint (multiple organ 
failures). All the three patients were considered operable at 
reevaluation.
Preoperative staging was performed with PET in four 
patients (33%), PET and brain magnetic resonance imaging 
in ﬁve patients (41.7%), PET and endobronchial ultrasound 
in one patient (8.3%; because of high SUV of mediastinal 
lymph nodes), and no information regarding preoperative 
staging was available in two patients (16.7%). In two patients, 
high uptake was noted in mediastinal lymph nodes on PET: in 
one of them, endobronchial ultrasound–transbronchial needle 
aspiration turned out negative on the PET-positive lymph node 
and the positive lymph node was considered as inflammatory 
in the other (biopsy was not done). Pulmonary function test 
was repeated preoperatively in all surgical patients. Vital 
capacities and forced expiratory volumes in 1 second were not 
statistically different from those obtained before SBRT (val-
ues not shown, p = 0.61).
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The surgical approach was determined at the surgeon’s 
discretion. The VATS approach was initially attempted in 
six patients (50%), but conversion to open thoracotomy 
was necessitated because of intraoperative bleeding in 
one. The bronchial stump was covered with pericardial fat 
pad in two patients (16.7%) and intercostal muscle in one 
patient (8.3%). Mediastinal lymph node dissection was 
performed in all patients but one. Postoperatively, pro-
longed air leak (>5 d) was seen in three patients (25%), but 
otherwise no postoperative complication was noted. Two 
TABLE 1. Pretreatment Patient Demographics and Tumor Characteristics
All (n = 49) Salvage Surgery (n = 12) Chemotherapy (n = 8) BSC (n = 29) P Valueb
Age at LR 78a (56–90) 76a (63–86) 78a (66–89) 80a (56–90) 0.10
Female gender 10 (20.4%) 0 3 (37.5%) 7 (24.1%) 0.06
CCI 1 (0–5) 1a (0–5) 0.5a (0–4) 2a (0–4) 0.89
ECOG PS 0.13
  0 or 1 45 (91.8%) 12 (100%) 8 (100%) 25 (86.2%)
  2 or 3 4 (8.2%) 0 0 4 (13.8%)
Pack-year 50a (0–165) 56.3a (0.5–90) 24.3a (0–100) 50a (0–165) 0.25
Smoking history 0.096
  Never 7 (14.3%) 0 3 (37.5%) 4 (13.8%)
  Previous 39 (79.6%) 12 (100%) 4 (50%) 23 (79.3%)
  Current 3 (6.1%) 0 1 (12.5%) 2 (6.9%)
Operable at SBRT 17 (34.7%) 9 (75%) 3 (37.5%) 5 (17.2%) 0.003
Operable at LR 17 (34.7%) 12 (100%) 3 (37.5%) 2 (6.9%) <0.0001
PFT at SBRT
  FEV1 (%) 67.6a (31.1–89.3) 66.7a (49.8–77.0) 71.0a (44–86) 68.8a (31.4–89.3) 0.88
  VC (%) 94.8a (49.3–125.9) 99.6a (80.2–123) 87.7a (61.8–105.8) 90.8a (49.3–125.9) 0.37
DFI 20.5a (4.4–109) 17.5a (8.6–105) 22.7a (8.8–108.4) 17.4a (4.4–109) 0.46
Histology 0.11
  Adenocarcinoma 16 (32.7%) 6 (50%) 5 (62.5%) 5 (17.2%)
  Squamous cell 19 (38.8%) 4 (33.3%) 2 (25%) 14 (48.3%)
  Large 1 (2.0%) 1 (8.3%) 0 0
  NSCLC, NOS 5 (10.2%) 1 (8.3%) 0 4 (13.8%)
  Unknown 7 (14.3%) 0 1 (12.5%) 6 (20.7%)
Tumor location 0.30
  RUL 14 (28.6%) 4 (33.3%) 2 (25%) 8 (27.6%)
  RML 4 (8.2%) 0 2 (25%) 2 (6.9%)
  RLL 11 (22.4%) 2 (16.7%) 1 (12.5%) 7 (24.1%)
  LUL 16 (32.7%) 6 (50%) 2 (25%) 8 (27.6%)
  LLL 5 (10.2%) 0 1 (12.5%) 4 (13.8%)
Tumor diameter at SBRT (mm) 25a (11–45) 22a (11–37) 28a (15–33) 25a (14–45) 0.54
Clinical T factor 0.67
  T1a 15 (30.6%) 3 (25%) 3 (37.5%) 9 (31.0%)
  T1b 18 (36.7%) 5 (42%) 2 (25%) 11 (37.9%)
  T2a 16 (32.7%) 4 (33%) 3 (37.5%) 9 (31.0%)
EGFR gene mutation 0.022
  Positive 4 (8.2%) 2 (16.7%) 2 (25%) 0
  Negative 8 (16.3%) 1 (8.3%) 0 7 (24.1%)
  No information 37 (75.5%) 9 (75%) 6 (75%) 22 (75.9%)
SBRT doses 0.69
  48 Gy/4 38 (77.6%) 10 (83.3%) 7 (87.5%) 21 (72.4%)
  56 Gy/4 4 (8.2%) 1 (8.3%) 0 3 (10.3%)
  60 Gy/8 7 (14.3%) 1 (8.3%) 1 (12.5%) 5 (17.2%)
aValues provided as median (range).
bThe p values provided in comparison of salvage surgery, chemotherapy, and BSC groups.
BSC, best supportive care; LR, local relapse; CCI, Charlson comorbidity index; ECOG PS, Eastern Cooperative Oncology Group performance status; SBRT, stereotactic body 
radiotherapy; PFT, pulmonary function test; FEV1, forced expiratory volume in one second: VC, vital capacity; DFI, disease-free interval; NSCLC NOS, non–small-cell lung cancer 
not otherwise speciﬁed; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; EGFR, epidermal growth factor receptor.
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patients (16.7%) with positive mediastinal lymph nodes 
on preoperative PET were positive on mediastinal lymph 
nodes on ﬁnal pathology and were offered adjuvant che-
motherapy (cisplatin and vinorelbine, two and four cycles, 
respectively), 5 and 8 weeks postoperatively, respectively. 
Viable tumor cells were found in the specimens of all 
12 patients.
Chemotherapy as Systemic Antitumor 
Therapy for Isolated LR
Chemotherapy as systemic antitumor therapy was per-
formed in eight patients: cytotoxic chemotherapy only in 
three patients and geﬁtinib in ﬁve patients. Patient demo-
graphics and survival outcomes receiving cytotoxic chemo-
therapy only or geﬁtinib are summarized in Table 3. Three 
patients (patients F, G, and H) were considered operable 
both at SBRT and at LR. Among ﬁve patients on geﬁtinib, 
two patients (patients D and H) were found to have epi-
dermal growth factor receptor (EGFR) gene mutations: an 
exon 19 E746-A750 deletion in one and an exon 21 L858R 
mutation in the other. No information on EGFR status was 
obtained in the other three patients.
Treatment Options for Patients 
Who Were Operable at SBRT
Seventeen of 49 patients in this study were considered 
operable at initial SBRT. Of them, nine patients underwent 
salvage surgery at LR, ﬁve persistently rejected salvage sur-
gery, preferring cytotoxic chemotherapy or geﬁtinib (N = 3) or 
BSC (N = 2). The rest of the three patients became inoperable 
at LR because of aggravated performance status (N = 2) or a 
postoperative complication of interim bladder cancer (N = 1). 
Survival outcomes in patients (N = 5) who were operable at 
SBRT and received BSC at LR were summarized in Table 4.
Survival Outcomes
OS from LR and that from SBRT are shown in 
Figure 1A and B, respectively. Five-year OS of the whole 
patient cohort, patients undergoing salvage surgery, those 
TABLE 2. Demographics and Outcomes in Patients Undergoing Salvage Surgery for Isolated Local Relapse after SBRT
Age
Initial Reason 
for Precluding 
Surgery
DFI 
(mo) His cTNM
Operative  
Procedure
Size of 
Resected 
Tumor (mm)
Intrapleural 
Adhesion Adjuvant pTNM
Current Status from 
Recurrence
64 Severe COPD, HD, 
and DM
11 Sq cT2N0M0 Open LUL 
lobectomy
34 No No pT2N0M0 Alive (86 mo), NED
76 Patient’s choice for 
SBRT (operable)
15 NSCLC, 
NOS
cT1N0M0 Open RUL 
lobectomy
50 No No pT2N0M0 Died (81 mo), from 
distant relapse
78 Patient’s choice for 
SBRT (operable)
105 Ad cT1N0M0 Open RUL 
lobectomy
25 No No pT1N0M0 Alive (78 mo), NED
86 Patient’s choice for 
SBRT (operable)
16 La cT1N0M0 Open LUL 
lobectomy
33 No No pT2N0M0 Died (35 mo), from 
subsequent colon 
cancer
77 Patient’s choice for 
SBRT (operable)
21 Sq cT1N0M0 VATS RUL 
lobectomy
28 No No pT1N0M0 Alive (60 mo), NED
70 Patient’s choice for 
SBRT (operable)
23 Ad cT1N0M0 VATS RUL 
lobectomy
32 No Chemo pT2N2M0 Alive (76 mo), with 
distant relapse (on 
erlotinib)
76 Patient’s choice for 
SBRT (operable)
10 Ad cT1N0M0 Open LUL 
lobectomy
12 No Chemo pT1N2M0 Alive (51 mo), with 
regional relapse (on 
geﬁtinib)
72 A recent progressed 
metachronous 
NSCLC, s/p 
CABG
43 Ad cT1N0M0 VATS left 
apicoposterior 
segmentectomy
12 No No pT1N0M0 Alive (58 mo), NED
74 s/p aortic arch 
replacement
18 Sq cT1N0M0 Open LUL wedge 
resection
33 Yes No pT1N0M0 Died (31 mo), from 
distant relapse
81 Patient’s choice for 
SBRT (operable)
29 Sq cT1N0M0 VATS right 
segmentectomies 
(lateral and 
posterior basals)
16 No No pT2N0M0 Alive (21 mo), NED
74 Patient’s choice for 
SBRT (operable)
21 Ad cT1N0M0 Open RLL 
lobectomy
42 No No pT2N0M0 Alive (20 mo), NED
85 Patient’s choice for 
SBRT (operable)
14 Ad cT2N0M0 VATS LUL 
lobectomy
NI Yes No pT2N0M0 Alive (3 mo), NED
SBRT, stereotactic body radiotherapy; DFI, disease-free interval; His, histology; cTNM, clinical tumor, node, metastasis; pTNM, pathological tumor, node, metastasis; COPD, 
chronic obstructive pulmonary disease; HD, hemodialysis; DM, diabetes mellitus; NSCLC, non–small-cell lung cancer; s/p, status post; CABG, coronary artery bypass grafting; Ad, 
adenocarcinoma; Sq, squamous cell carcinoma; La, large-cell carcinoma; VATS, video-assisted thoracoscopic surgery; LUL, left upper lobe; RUL, right upper lobe; RLL, right lower 
lobe; NI, no information; Chemo, chemotherapy; NED, no evidence of disease; M, months.
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undergoing chemotherapy, and those receiving BSC was 
47.9% (95% conﬁdence interval [CI]: 32.9–62.9), 79.5% 
(95% CI: 44.6–94.9), 60.0% (95% CI: 25.4–86.9), and 
31.5% (95% CI: 13.6–49.6), from initial SBRT. Median OS 
of the whole patient cohort, patients undergoing salvage sur-
gery, those undergoing chemotherapy, and those receiving 
BSC was 50.8 months, not reached, 68.5 months, and 31.9 
months, from initial SBRT.
Five-year OS of the whole patient cohort, patients under-
going salvage surgery, those undergoing chemotherapy, and 
those receiving BSC was 25.7% (95% CI: 11.1–40.3), 79.5% 
(95% CI: 44.6–94.9), 0%, and not reached, from LR. Median 
OS of the whole patient cohort, patients undergoing salvage 
surgery, those undergoing chemotherapy, and those receiving 
BSC was 25.0, 82.7, 38.5, and 10.5 months, from LR.
CSS from LR and that from SBRT are shown in Figure 
2A and B, respectively. Five-year CSS of the whole patient 
cohort, patients undergoing salvage surgery, those undergo-
ing chemotherapy, and those receiving BSC was 56.9% (95% 
CI: 42.2–71.7), 90.9% (95% CI: 56.1–98.7), 75.0% (95% 
CI: 37.7–93.7), and 36.1% (95% CI: 16.7–55.4) from ini-
tial SBRT. Median CSS of the whole patient cohort, patients 
undergoing salvage surgery, those undergoing chemotherapy, 
and those receiving BSC was 68.5 months, not reached, 80.0 
months, and 29.7 months, from initial SBRT.
Five-year CSS of the whole patient cohort, patients 
undergoing salvage surgery, those undergoing chemotherapy, 
and those receiving BSC was 36.7% (95% CI: 18.8–54.6), 
90.9% (95% CI: 56.1–98.7), 0%, and not reached from LR. 
Median CSS of the whole patient cohort, patients undergo-
ing salvage surgery, those undergoing chemotherapy, and 
those receiving BSC was 29.7, 82.7, 43.9, and 12.0 months, 
from LR.
Hazard ratios, 95% conﬁdence intervals, and p values 
of potential prognostic factors of survival outcomes (OS and 
CSS) from LR in univariate and multivariate analyses are 
shown in Table 5. In multivariate analysis, salvage surgery 
was a signiﬁcant prognostic factor of OS and CSS from LR.
DISCUSSION
SBRT is a reasonable alternative to surgical resection 
for early-stage NSCLC in medically compromised or inoper-
able patients.2–4 Our previous studies suggested that the role of 
SBRT in low-risk operable patients tolerating a lobectomy has 
remained to be determined,25 whereas SBRT may be a promis-
ing alternative in patients at high risk for a lobectomy,8 which 
is consistent with other international data.5,6
Any improvement in salvage treatments for relapse after 
SBRT can contribute to more favorable survival outcomes in 
patients undergoing SBRT for early-stage NSCLC. The most 
frequent pattern of relapse after SBRT for early-stage NSCLC 
is reported to be distant with LR being less common than 
regional or distant relapse.9,26,27 The deﬁnition and detection 
of LR seem more challenging than detection of regional or 
distant relapse because LR is seen in previously irradiated 
areas. The deﬁnition of LR varies across institutions. Biopsy 
conﬁrmation is not a common practice (the reported rate of 
biopsy conﬁrmation in presumable LR ranges from 17.6% to 
TABLE 3. Demographics and Outcomes in Patients Undergoing Chemotherapy (Cytotoxic Chemotherapy Only or Gefitinib) 
for Isolated Local Relapse after SBRT
Age Sex His CCI DFI (mo) Treatment Toxicities Subsequent Tx Survival from Local Relapse
A 73 M Ad 3 24.5 Geﬁtinib NI NI Cancer death (44 mo)
B 78 F Ad 4 55.1 Geﬁtinib Eczema PEM Cancer death (24 mo)
C 75 M Sq 2 12.8 CBDCA + PTX None DTX, VNR, Erlotinib Cancer death (29 mo)
D 78 F Ad 0 41.0 Geﬁtinib None no Alive (39 mo)
E 66 M UK 0 20.8 DTX NI NI Noncancer death (38 mo)
F 89 F Ad 1 108.3 Geﬁtinib NI NI Cancer death (51 mo)
G 77 M Sq 0 8.8 DTX BM suppression NI Cancer death (22 mo)
H 78 M Ad 0 20.9 Geﬁtinib None No Alive (25 mo)
SBRT, stereotactic body radiotherapy; His, histology; CCI, Charlson comorbidity index; DFI, disease-free interval; Tx, treatment; inop, inoperable; Hx, history; M, male; F, female; 
Ad, adenocarcinoma; Sq, squamous cell carcinoma; UK, unknown; NI, no information; CBDCA, carboplatin; PTX, paclitaxel; DTX, docetaxel; BM, bone marrow; PEM, pemetrexed; 
VNR, vinorelbine.
TABLE 4. Demographics and Survival Outcomes in Patients (N = 5) Who Were Operable at SBRT but Received Best Supportive 
Care at LR
Age/Sex DFI (mo) CCI Operability at LR Comment Survival from SBRT
78/male 28 1 Inoperable Performance status aggravated Died, 29 mo
76/male 29 1 Operable Rejected surgery again Died, 37 mo
79/male 15 3 Inoperable Another malignancy Died, 16 mo
81/female 7 1 Inoperable Performance status aggravated Died, 37 mo
85/female 31 1 Operable Rejected surgery again Alive, 47 mo
SBRT, stereotactic body radiotherapy; DFI, disease-free interval; CCI, Charlson comorbidity index; LR, local relapse.
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87.5%13,28–30), or not reported in other studies.31–35 LR is usu-
ally diagnosed by radiological studies, and PET-CT is more 
speciﬁc in this setting than CT alone.13,28,29,32 On PET, an 
SUVmax of greater than 5 is more likely associated with LR 
rather than radiation pneumonitis after SBRT,14,28,30 and this 
association has been validated in another study.11
As discussed above, many efforts have been made 
to detect LR after SBRT; however, little is known about 
long-term outcomes of salvage treatments or BSC. Any sal-
vage treatment for LR would be challenging for presumably 
compromised patients undergoing SBRT. Reported percent-
ages of patients with LR after SBRT who undergo salvage 
treatment range widely from 24% to 100%.17,20 Previously 
reported salvage treatments for isolated LR after SBRT for 
early-stage NSCLC included salvage surgery18–21 and repeated 
SBRT.17
FIGURE 1. Kaplan–Meier estimates of overall survival (OS) from local relapse (LR) (A) and from SBRT (B). Black solid line, 
patients undergoing salvage surgery; grey solid line, those undergoing chemotherapy; black dotted line, those receiving best 
supportive care.
FIGURE 2. Kaplan–Meier estimates of cancer-specific survival (CSS) from local relapse (LR) (A) and from SBRT (B): Black solid 
line, patients undergoing salvage surgery; grey solid line, those undergoing chemotherapy; black dotted line, those receiving 
best supportive care.
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By comparing patient demographics and tumor character-
istics between salvage treatment groups, we attempted to identify 
signiﬁcant measurable factors that may guide treatment. The only 
signiﬁcant preoperative factor was operability at SBRT and at 
LR. However, operability is an unmeasurable factor difﬁcult to 
deﬁne and presumably a factor that largely derives from multidis-
ciplinary conferences between radiation oncologists and thoracic 
surgeons. It should be emphasized that operability be discussed 
multiple times, not only at SBRT but also at LR because operabil-
ity is not always constant or ﬁxed20,21 as in our series. In our series, 
of 12 patients undergoing salvage surgery, three patients were 
considered inoperable at SBRT from different standpoints but 
became operable at reevaluation. Conversely, as in our patients, 
a portion of operable patients at SBRT can become inoperable at 
LR, which is inevitable over the course of time.
One technical factor that makes us hesitant to proceed 
with salvage surgery is potential intrapleural adhesions that are 
presumably derived from SBRT and may preclude a minimally 
invasive approach, among previous reports on salvage surgery 
after SBRT. There was no intrapleural adhesion in either case 
in Neri et al.’s19 report, there is no description on adhesions in 
Taira et al.’s21 report, or intrapleural adhesions were noted in 
two patients (16.7%) in our series, whereas adhesions were 
reported in all patients in Allibhai et al.’s20 study. In our series, 
5 of 12 (41.7%) of patients were operated on through VATS in 
contrast to the report of Allibhai et al.20 Selection of the surgical 
approach in our series was largely dependent on the surgeon’s 
discretion, and our ﬁndings suggest that minimally invasive 
thoracic surgery or VATS seems feasible at least in a subset of 
patients undergoing salvage surgery after SBRT, which would 
be an advantage in perioperative outcomes,35 especially in car-
diopulmonary-compromised patients,36 when comparable with 
open thoracotomy. Previous irradiation can delay bronchial 
healing after anatomical pulmonary resections, but no informa-
tion on coverage of the bronchial stump in salvage surgery was 
available in previous studies. In our series, 25% of the patients 
undergoing salvage surgery had a bronchial stump coverage at 
the discretion of the surgeon. A majority of patients undergoing 
induction therapy and surgical resection for advanced NSCLC 
had a bronchial stump coverage37,38 to prevent bronchopleural 
ﬁstulae, but whether bronchial stump coverage is required in 
salvage surgery remains unknown given the differences in time 
since irradiation and peripheral locations of tumors.
The absence of perioperative mortality and the low 
perioperative morbidity rate of 25% in our study suggest that 
upfront SBRT followed by salvage surgery in cases of LR is 
a viable option in patients with multiple comorbidities or in 
those hesitant to undergo primary surgery. The short-term out-
comes of salvage surgery seem comparable to those of lobec-
tomy for NSCLC as a ﬁrst treatment35 and far better than those 
of reoperative pulmonary resection.39 Despite the small sam-
ple size, long-term survival outcomes of our surgical patients 
seem comparable to those of lobectomy as a ﬁrst treatment.35
Salvage surgery plays a diagnostic role as well to judge 
if radiologic features really reflect a local recurrence after 
SBRT because comprehensive histopathological examination 
of the whole tumor (to detect viable cells) is only possible after 
surgical resection of the tumor. All our patients undergoing 
TABLE 5. Hazard Ratios and 95% CI of Potential Prognostic Factors of OS and CSS from LR in Univariate and Multivariate Analysis
OS CSS
HR 95% CI P Value HR 95% CI P Value
Univariate analysis
  Age at LR (per 1 year) 1.05 1.00–1.10 0.043 1.06 1.00–1.13 0.038
  Male gender 1.07 0.44–1.33 0.73 1.007 0.57–1.52 0.069
  Disease-free interval (per 1 year) 1.06 0.75–1.08 0.42 1.65 1.023–1.84 0.014
  Tumor histology (Ad vs. non-Ad) 0.46 0.27–1.22 0.21 4.1 0.85–15.9 0.08
  Initial tumor size 1.02 0.97–1.07 0.39 1.02 0.97–1.07 0.39
  Tumor location (upper and middle vs. lower lobes) 0.53 0.24–1.22 0.13 0.66 0.27–1.79 0.40
  Performance status (2–3 vs. 0–1) 1.1 0.38–1.61 0.74 1.01 0.1–1.37 0.97
  Charlson comorbidity index (per one) 1.06 0.78–1.31 0.67 1.006 0.69–1.29 0.97
  Vital capacity (per 1%) 0.99 0.98–1.02 0.68 1.007 0.99–1.03 0.51
  FEV1 (per 1%) 0.99 0.96–1.02 0.50 1.004 0.71–1.04 0.80
  Smoking history (never vs. current) 1.96 0.33–37.4 0.50 1.36 0.20–26.9 0.94
  Pack-year (per 1) 1.01 0.99–1.02 0.20 1.01 0.99–1.02 0.057
  Inoperable 2.36 1.29–3.94 0.0001 1.83 1.27–2.57 0.03
  Treatment (nonsurgical vs. surgery) 2.23 1.58–3.2 <0.0001 36.3 6.04–740 <0.0001
Multivariate analysis
  Age at LR (per 1 year) 1.03 0.97–1.08 0.31 1.05 0.99–1.34 0.0095
  Inoperable 1.36 0.83–2.04 0.19 1.06 0.51–1.80 0.84
  Disease-free interval (per 1 year) NA NA NA 1.3 1.12–1.91 0.0033
  Treatment (nonsurgical vs. surgery) 2.23 1.58–3.2 0.014 63 6.2–218.1 0.0001
HR, hazard ratio; CI, conﬁdence interval; LR, local relapse; LLL, left lower lobe; LUL, left upper lobe; RUL, right upper lobe; FEV1, forced expiratory volume in one second; 
BSC, best supportive care; Chemo, chemotherapy; NA, not applicable, OS, overall survival; CCS, cancer-speciﬁc survival.
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salvage surgery had viable tumor cells in the specimens. Taira 
et al.21 reported salvage surgery for two cases with low 
SUVmax (2.7 and 1.9) resulting in no viable cells in the 
resected tumor. In Neri et al.’s19 report, two patients were noted 
to have high SUVmax (9.4 and 12.2) along with viable cells 
in the resected mass. Of interest, one patient from Allibhai 
et al.’s20 report had high SUVmax (8.9) but no viable cells in 
the resected mass. Future studies from other institutions are 
expected to add to the information on the relationship between 
SUVmax and viable cells.
To date, cytotoxic chemotherapy or EGFR-tyrosine 
kinase inhibitor treatment for isolated LR after SBRT for early-
stage NSCLC has not been reported. To date, chemotherapy 
after SBRT has been discussed only in the adjuvant setting 
for large or centrally located tumors treated with SBRT.40 In 
Chen et al.’s40 study, 17 patients were offered adjuvant chemo-
therapy with three to four cycles of cisplatin-based regimens 
1 week after SBRT. Patients older than 75 years and those with 
comorbidities were not administered adjuvant chemotherapy. 
As a result, toxicities were mild, of grade 2 or lower severity. 
Song and Zhang41 suggested geﬁtinib as a salvage treatment in 
patients with EGFR mutation who failed to respond to radio-
therapy for brain metastases of NSCLC.41 Imai et al.’s42 study 
suggested that these patients beneﬁt more from EGFR-tyrosine 
kinase inhibitors than from radiotherapy. Although data are 
limited, it seems reasonable to consider EGFR-tyrosine kinase 
inhibitors for patients with EGFR mutation because no serious 
complication was noted in our study.
No patient in our study underwent repeat SBRT or 
other radioablative procedures for LR of NSCLC, and there 
is a paucity of literature regarding repeat SBRT for LR of 
NSCLC.17,42–45 Each study contained a small patient cohort 
undergoing repeat SBRT more than 12 months after ﬁrst SBRT, 
with a short follow-up period ranging from 12 to 22 months 
(of median). The toxicities ranged from grades 2 to 5. As sug-
gested by the authors, further studies are required to evaluate 
the outcomes and the indications. Once long-term survival 
outcomes are available, we may consider repeat SBRT, espe-
cially for select inoperable patients with LR.
The limitations of this study included its retrospective 
study design and the single center experience. Our study is 
also limited by the relatively small sample size. Another limi-
tation would be that biopsy conﬁrmation was not possible in 
all SBRT-treated patients in other studies.46 More importantly, 
the majority of LR in our study were biopsy proven and there 
may be false-positives in our patients managed nonsurgically. 
Although most patients of the entire cohort underwent PET, 
SUVmax was unavailable in most of these patients.
Despite these limitations, our results are based on the 
largest data set to date, with a long follow-up period after sal-
vage treatments for isolated LR after SBRT. To obtain a larger 
sample size and identify signiﬁcant prognostic factors after 
salvage surgery, a multi-institutional study of either a retro-
spective or prospective design is required.
CONCLUSIONS
We characterized salvage treatment options for isolated 
LR after SBRT for early-stage NSCLC. Our results suggest 
salvage surgery for isolated LR can be undertaken safely with 
favorable survival outcomes and that it is recommended to 
select patients with isolated LR. It should be emphasized that 
operability at LR be discussed at multidisciplinary confer-
ences. Long-term and continued follow-up is required espe-
cially for patients with reasonable functional status undergoing 
SBRT for NSCLC.
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